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Available online 30 April 2011Given the controversy about the comparative efficacy of first- compared with second-generation
antipsychotics in the treatment of schizophrenia, more large-scale evidence is needed to guide
clinicians in their prescriptions. Most randomized controlled trials (RCTs) were conducted in
centers of excellence on highly selected samples, poorly representative of real-world patients, and
often suffered conflicts of interest as they were sponsored by drug companies.
The primary aim of the present study is to compare the effectiveness of haloperidol, olanzapine
and aripiprazole in a representative sample of schizophrenia patients. The GiSAS trial is an
open-label, independent, pragmatic RCT in Italian community-based public psychiatric
services. At least 260 patients meeting the DSM-IV criteria for schizophrenia will be randomly
allocated to one of the study drugs and followed up for one year. A two-year observational
phase will follow. The primary outcome for tolerability will be the onset of metabolic
syndrome. The primary endpoint for effectiveness will be discontinuation of antipsychotic
monotherapy. Secondary measures include global functioning, time to discontinuation due to
side-effects, change of lipid profile, extrapyramidal symptoms and other adverse effects.
In the last four years, the GiSAS study group has been working to implement this multicenter
RCT. The trial mechanism is now fully functional and working. As of end of February 2011, 260
subjects were randomized by 54 study investigators in 33 out of 43 participating centers.
© 2011 Elsevier Inc. All rights reserved.Keywords:
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Schizophrenia is a serious and disabling mental illness
causing positive symptoms (such as delusions and halluci-
nations) and negative ones (such as lack of motivation and
social withdrawal). Schizophrenic disorders can have far-
reaching negative effects on personality, cognition, global
functioning and quality of life and usually need long-term
therapy.
The short-term beneﬁts of ﬁrst-generation antipsychotics
(FGAs) in controlling positive symptoms are well documen-
ted, as are their high rates of extrapyramidal side-effects.
However, long-term data are still few and there is no
convincing evidence that FGAs have any effect on the
negative symptoms [1–3]. Second-generation antipsychotics
(SGAs) claim to be more effective and better tolerated than
FGAs. However, early reviews questioned their advantages
[4,5]. Although there is evidence of a lower risk of neurologic
side-effects, they are reported to cause metabolic side-effects
like weight gain, dyslipidemia and impaired fasting glucose
[6]. Only clozapine proved clearly superior and was effective
in non-responders to other antipsychotics, but severe side-
effects limit its use in community settings [7,8].
Initial enthusiasm for the “atypical” effect of SGAs has
gradually waned, and concern has grown about their high
costs [9,10]. Researchers have become increasingly suspicious
about the evidence on antipsychotics, most of which comes
from industry-sponsored trials [11,12].
In a recent meta-analysis some SGAs showed more effect
than FGAs in terms of symptom relief, with small effect sizes
for amisulpride, olanzapine and risperidone and only a
medium effect size for clozapine [13]. However, in another
meta-analysis focusing on the metabolic side-effects of SGAs,
olanzapine and clozapine had the worst proﬁle [14].
Recently three landmark pragmatic and independent
studies have cast further doubts on the effectiveness of
SGAs compared to FGAs in schizophrenia (see Table 1) [15–
23]. The US CATIE phase 1 study was a double-blind trial in
which 1493 patients with chronic schizophrenia were
randomized to one of the SGAs olanzapine, quetiapine,
risperidone or to the FGA perphenazine, and followed up
for 18 months [17]. The CATIE trial included a phase 2 where
discontinuers were re-randomized to an open-label compar-
ison between clozapine and the remaining SGAs [18]. The UK
CUtLASS study comprised two smaller open-label trials
comparing FGAs and SGAs in terms of quality of life at oneTable 1
Examples of independently funded pragmatic RCT on long-term effectiveness of an
CATIE — phase 1 CUtLASS 1 EUFE
Design Double-blind Open-label (rater-blinded) Ope
Follow-up 18 months 12 months 12 m
Study drugs Olanzapine vs.
perfenazine vs.
quetiapine vs.
risperidone
FGA vs. SGA Halo
olan
Primary endpoint Time to study drug
discontinuation
Quality of life Time
Participating centers 57 US 14 UK 50 (
Patients (no.) 1432 227 498
Funding NIMH NHS EGRyear [19,20]. CATIE and CUtLASS both found no signiﬁcant
differences between SGAs and FGAs in terms of effectiveness
or tolerability [17,19]. However, they found clozapine more
effective in refractory schizophrenia, and FGAs were more
cost-effective than SGAs [18,20].
The European First Episode Schizophrenia Trial (EUFEST)
study compared the effectiveness of low-dose haloperidol or
SGAs in ﬁrst-episode schizophrenia [21]. Treatment was
discontinued more by patients on haloperidol, but since
discontinuation rates were not consistent with symptomatic
improvement the superiority of SGAs was not conﬁrmed.
Finally, two papers presenting data from CATIE and EUFEST
reported no signiﬁcant differences between FGAs and SGAs in
terms of cognitive test performance [22,23].
2. Material and methods
2.1. Study hypothesis
All these ﬁndings fueled disagreement among researchers
and clinicians instead of resolving the controversy about the
comparative effectiveness of antipsychotic medications. This
may be partly due to the fact that SGAs are not a
homogeneous category, as they differ in many properties
and comprise both old drugs, like clozapine and amisulpride,
and the newer one, like aripiprazole and ziprasidone. In a
recent critical review Leucht and colleagues concluded that
although atypical antipsychotics are not a breakthrough, the
overall evidence in favor of some of them is consistent. Thus,
the debate for or against SGAs seems to be inﬂuencedmore by
values than by data [24].
These conﬂicting views call for more pragmatic evidence
to guide clinicians. Therefore, the Italian Group for the Study
of Second-generation Antipsychotics (GiSAS) decided to
design a pragmatic, open-label RCT to compare old and new
antipsychotics in people with schizophrenia treated in
routine Italian clinical settings.
Since the controversy on the comparative efﬁcacy of SGAs
over FGAs was not settled by the latest pragmatic RCTs we
proposed a trial focused on tolerability. Adverse reactions like
metabolic disturbances or extrapyramidal symptoms (EPS)
are extremely common with antipsychotic treatment. More-
over, best available evidence shows that differences in terms
of side-effects among SGAs are larger and clinically more
relevant than differences in efﬁcacy [14]. Thus, GiSAS was
designed to ﬁnd out whether any one of the selectedtipsychotic therapy in schizophrenia.
ST GiSAS
n-label Open-label (analyst-blinded)
onths 12 months
peridol vs. [amisulpride,
zapine, quetiapine, ziprasidone]
Aripiprazole vs. [olanzapine,
haloperidol]
to study drug discontinuation Staying on study drug without
developing metabolic syndrome
14 UE countries) 43 ITA
260
IS (Pﬁzer, AstraZeneca, Sanoﬁ-Aventis) MNegri (Bristol-Myers Squibb)
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uation and caused less harm than the others.
The study drugs were selected taking account of tolera-
bility and current prescribing practice in Italy. We opted for a
comparison between two SGAs and one FGA. Clozapine was
excluded because of its peculiar side-effect proﬁle and
difﬁcult management. Thus, among the other SGAs (i.e.
amisulpride, risperidone, olanzapine, quetiapine, and aripi-
prazole) we selected aripiprazole and olanzapine.
When the trial was being planned (2006) aripiprazole was
the latest and promising antipsychotic with a good but only
preliminary reputation for tolerability (i.e. metabolic and
EPS) and a still doubtful reputation for effectiveness. It was
believed to work as a D2-antagonist in pathways where an
excess of dopamine produces psychosis, and as a D2-agonist
at sites where low dopaminergic tone would produce motor
side-effects and increased prolactin release [25]. It was
associated with a low likelihood of inducing EPS, sedation,
QTc prolongation, weight gain and metabolic abnormalities.
However, evidence on its effectiveness and tolerability was
still scant and its hypothetically different proﬁle of therapeu-
tic and adverse effects was not yet proven [26].
Olanzapine is a widely used SGA and has for many years
been the most prescribed antipsychotic in Italy [27]. It had an
excellent reputation for efﬁcacy, and was known to cause few
EPS; however, it did have adverse effects on body weight
[9,28].
Lastly, we selected haloperidol a highly potent and
effective FGA and the most widely used comparator in clinical
trials investigating the efﬁcacy of antipsychotic drugs for
schizophrenia [9]. The use of haloperidol as control drug for
randomized trials of new antipsychotics has been questioned
for its propensity to cause EPS [29]. Movement disorders,
however, mostly arose with high doses of haloperidol
[5,29,30], and, in fact, Geddes and colleagues (2000)
concluded that trials showing SGAs to be superior to
haloperidol used too high doses of the latter [5]. It has
therefore been argued that haloperidol's comparative effec-
tiveness might improve with a more prudent dosing
approach, although this has not been conﬁrmed in recent
reviews [9]. On the other hand, haloperidol has low
propensity to cause metabolic side-effects, although this too
has never been thoroughly investigated [31]. Haloperidol is
the most prescribed FGA worldwide and is still widely
prescribed in Italy, where a strong tradition of low dosing
may have resulted in less criticism [27].
The GiSAS trial was conceived to be large enough to
identify small to moderate differences in treatment effects
and simple enough to be introduced in non-academic
community mental health services. Our purpose was to
compare FGAs and SGAs in terms of tolerability and
effectiveness, so as to detect meaningful differences. There-
fore we focused on two sound endpoints: metabolic syn-
drome and treatment discontinuation. As the tendency of
haloperidol to cause more EPS was well known, and available
ﬁndings did not suggest relevant differences in terms of EPS
between olanzapine and aripiprazole, those neurological
side-effects were adopted as secondary endpoints [2,4,26].
The metabolic syndrome is a constellation of closely
related risk factors and represents a way of assimilating risk
across the various pathogenic pathways related to obesity. Inthis study metabolic syndrome was diagnosed on the basis of
at least three of the criteria indicated by the Adult Treatment
Panel III (ATP III) [32]:
1. Abdominal obesity (waist circumference N102 cm in men
and N88 cm in women);
2. Fasting triglycerides ≥150 mg/dL;
3. High-density lipoprotein b40 mg/dL in men or b50 mg/dL
in women;
4. High blood pressure ≥130/85 mm Hg or on antihyperten-
sive medication;
5. Fasting glucose≥110 mg/dL or on insulin or hypoglycemic
medication.
Patients with schizophrenia have a mortality rate two to
three times higher than the general population mainly due to
suicide and natural causes, including cardiovascular diseases
[33,34]. Although their lifestyle may contribute to the higher
mortality [35], a role has also been attributed to antipsychotic
medications, through direct effects on cardiac repolarization,
possibly leading to sudden cardiac death, and to metabolic
syndrome [34,36,37].
Long-term antipsychotic prescription has become one of
the cornerstones of treatment for psychotic disorders. Patients
on antipsychotic medication do better overall and early
cessation often results in higher relapse rates, hospitalization
and risk of death and violence [38–40]. Nevertheless,
medication management remains a serious problem as some
reports give rates of drug non-adherence around 50% [41].
Poor efﬁcacy and intolerable side-effects are common and
contribute to premature discontinuation. The CATIE and
EUFEST trials adopted time to all-cause treatment discontin-
uation as primary endpoint. Though poor symptom response
has been indicated as the main reason for antipsychotic
discontinuation in clinical trials [42,43], antipsychotic discon-
tinuation is considered a global indicator of treatment tenure
and a proxy measure of efﬁcacy, safety, and tolerability.
2.2. Study aims
Given the controversy on the comparative efﬁcacy of FGAs
over SGAs, clinicians should face substantial uncertainty in
the choice of the antipsychotic likely to provide greatest
clinical beneﬁt in adult patients with no speciﬁc contra-
indications, who have responded inadequately to previous
antipsychotic medication. The clinical question posed in the
GiSAS trial therefore concerns the relative tolerability and
effectiveness of aripiprazole, olanzapine and haloperidol in
the medium- and long-term treatment of schizophrenia, in
terms of metabolic syndrome onset and drug discontinuation.
2.3. Study design
The GISAS trial is an open label, one-year randomized
controlled trial ﬁrmly rooted in everyday clinical practice. To
enhance representativeness, the inclusion criteria are wide
and recruitment takes place in a broad array of clinical
settings and across the various components of service
provision. The sample is meant to be heterogeneous and to
reﬂect the real population attending Italian community
psychiatric services, recruiting a broad range of “real-world”
patients, including those with comorbid conditions.
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monotherapy with one of the study drugs. The study is not
designed to replace any aspect of the usual clinical care.
During follow-up, participants will be seen as often as is
usually clinically indicated. Each patient will be examined in
the respective recruiting center by the usual clinician.
At the end of the 12-month follow-up, all those random-
ized will enter a two-year prospective observational study.
2.4. Sample selection
Inclusion criteria:
• age 18 years and over;
• DSM-IV diagnosis of schizophrenia, based on the Mini
International Neuropsychiatric Interview [44];
• patients entering the study should, according to their own
judgment and in consultation with their doctor, have a
condition appropriate for changing current antipsychotic
treatment.
Exclusion criteria:
• metabolic syndrome diagnosed on the basis of at least three
of the criteria listed above;
• diabetes mellitus type II;
• any organic condition clearly contraindicating treatment
with any of the drugs (e.g. pregnancy or breast-feeding);
• known ineffectiveness or intolerance of one of the study
drugs, which is consequently contraindicated;
• patients who have never been exposed to antipsychotic
drugs;
• in the clinician's opinion, it is unlikely that the patient can
be followed-up for the whole study (one year).
2.5. Recruitment
Recruitment is conducted in a broad array of community
settings: outpatient clinics, acute hospital units, residential
facilities and day centers. Patients meeting the inclusion
criteria are asked to participate and, after giving fully informed
consent, can access randomization. Once randomized, they
are included in the study if they take at least one dose of the
assigned medication. The recruitment forms of patients
excluded are ﬁled and periodically reconsidered for inclusion.
2.6. Randomization
Eligible patients are randomized to the three treatment arms
following a 1:1:1 procedure. Randomization is stratiﬁed by site.
Although the number of criteria already satisﬁed in a patient at
studyentrymaybeapowerful predictor ofdevelopingmetabolic
syndrome during follow-up, the small numbers recruited per
center make it impossible to stratify for this variable too. A
secondary statistical analysis of the primary outcomewill adjust
for the number of criteria already met at study entry.
The allocation sequence (computer-generated random
sequence) has been registered before the trial's start. In-
vestigators are unaware of how exactly the chosen random-
ization method is being implemented.
Central randomization by telephone with an interactive
voice response system has been adopted. Investigators assesseligibility, gain consent, and make the decision to enroll a
patient at the participating site, then call the randomization
service to get the treatment allocation and the patient's code.
All records on the randomization database (e.g. failed calls,
unregistered randomizations) will be checked to detect any
attempts to decipher allocation.
2.7. Outcomes
The onset of metabolic syndrome was adopted as primary
negative endpoint. However, the trial takes account of two
primary endpoints: one for tolerability and one for effective-
ness [45,46].
2.7.1. Primary endpoint for tolerability
Patients who did not develop metabolic syndrome after a
year-long trial of the antipsychotic will be considered
treatment successes. The onsets of metabolic syndrome,
deﬁned by meeting at least three of the above listed criteria,
will be considered treatment failures even if the patients had
one or two clinical signs of metabolic syndrome at study
entry. The onset of metabolic syndrome must be recorded at
the end of the trial or when the assigned monotherapy is
stopped/changed or a second antipsychotic is added. Analyses
are centralized and metabolic syndrome parameters are
assessed in the same reference laboratory.
2.7.2. Primary endpoint for effectiveness
All-cause discontinuation of the allocated monotherapy
during follow-up will be considered treatment failure.
Switching to another antipsychotic, adding a second one or
stopping the assigned drug is classiﬁed as study drug
discontinuation. Reasons for discontinuing the assigned
antipsychotic are registered but not considered in the
primary outcome (Fig. 1).
Patients who meet the criteria for drug discontinuation
are counted as treatment failures with regard to effectiveness
but are followed up for the rest of the year.
In order to capture whether, when and why participants
stop the assigned treatment or add concomitant medication,
ongoing treatments are closely monitored. Occasional paren-
teral antipsychotic drug administration (e.g. during emer-
gency admission) will be allowed. A temporary stop of the
assigned antipsychotic (no longer than two weeks in six
months) will not be considered discontinuation.
The proportions of subjects in the three study groups who
discontinue treatment during the 12-month follow-up will be
compared. Time to discontinuation will be taken into account
in the secondary analysis.
2.7.3. Secondary endpoints
The following secondary endpoints will be taken into
account:
• reasons for study drug discontinuation;
• Global Assessment of Functioning score (GAF) [47];
• patients' subjective reports of adverse effects, assessed by
the Liverpool University Neuroleptic Side Effect Rating Scale
(LUNSERS) [48];
• worsening of metabolic proﬁle, deﬁned as the onset of at
least one metabolic syndrome criterion;
Fig. 1. The study drug discontinuation module in the trial monitoring form.
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• waist-to-hip-ratio (ratio of waist to hip circumferences);
• electrocardiographic abnormalities;
• hyperprolactinemia;
• EPS: evaluated through physical examination by clinicians,
and derived directly from speciﬁc LUNSERS items and
indirectly from the use of antiparkinson drugs;
• concurrent psychotropic medication, to pragmatically eval-
uate the occurrence of further psychiatric symptoms or
changes in different dimensions of psychopathology.2.8. Study medications
All the study drugs are currently licensed and marketed in
Italy for the treatment of schizophrenia. After randomization,
the daily oral drug doses will be prescribed according to usual
care practice and adjusted according to individual response
and side-effects. Although clinicians will not be obliged to
follow strict dose ranges, suggested doses are as follows:
• Aripiprazole 10 mg/day starting dose and 10–30 mg/day
dose range.
• Olanzapine 5 mg/day starting dose and 10–20 mg/day dose
range.
• Haloperidol 1–3 mg/day starting dose and 3–10 mg/day
dose range.For patients already taking an antipsychotic medication
prior to study entry, tapering the previous medication over a
period of at least four weeks is suggested. Reasons for being
switched will be recorded and used in the secondary analyses
to control for a prior disposition to resistance or intolerance.
Guidelines will be provided to help physicians choose the
switching strategy that is the best for each patient, with
which the patient is most comfortable. The continued use of
concomitant antipsychotic medication at the end of the
switch period is considered a discontinuation of the allocated
trial drug.
After inclusion few limits are imposed and clinicians will
be free to treat patients at their own discretion. Concomitant
psychotropic medication (e.g. benzodiazepines, antidepres-
sants) or non-psychotropic drugs (e.g. anticholinergic drugs,
beta-blockers, statins) are allowed and must be routinely
recorded. Data on their prescription will be used in the
secondary analyses.
Mood stabilizers will be allowed only for patients who
were taking these medications prior to study entry, as their
use is associated with metabolic disturbances.
2.9. Masking
Those who are directly involved in patients' care are not
blinded. In blinded trials clinicians are not perfectly able to
tune and adjust the optimal dose to the individual patients.
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reﬂects real clinical practice, increases its external validity
and consequently the generalizability of the results.
All the people involved in GiSAS trial coordination,
supervision, and data analysis are blinded.
2.10. Follow-up evaluations
Patients will be assessed (a) at baseline, (b) when
monotherapy is stopped or changed and (c) at 12 months.
Thus, at the end of the trial all subjects are re-assessed even if
they have stopped or changed the assigned drug.
During the one-year follow-up, participants will be seen as
often as usually clinically indicated (about once a month). On
these occasions investigators will be asked to complete a
speciﬁc monitoring form to check if any change in the
patient's medication has occurred (see Fig. 1).
With the exception of the centralized analyses, which are
done at the Mario Negri Institute to detect metabolic
disturbances, each patient is examined by the usual clinician
in the respective recruiting center. Any psychosocial inter-
vention provided by services during the study is monitored
and recorded.
2.11. Data analysis
All analyses will be by full intention-to-treat (ITT)
including all randomized participants who receive at least
one dose of the investigational drugs. Patients already taking
one of the study drugs at study entry can never be excluded
from the ITT analysis. Data will be analyzed using a last-
observation-carried-forward approach. Patients with no
follow-up data will be allocated to the outcome category of
treatment failure. In addition a “per protocol” analysis will be
done comparing patients who actually used the study drugs.
2.11.1. Primary outcome indicators
The proportion of participants in each treatment arm who
do not develop metabolic syndrome during follow-up is
adopted as primary endpoint for tolerability. The proportion
of patients who continue the allocated antipsychotic as
monotherapy in each treatment arm for the whole year is
adopted as primary endpoint for effectiveness.
2.11.2. Secondary outcome indicators
Mean GAF scores in each treatment armwill be compared.
Covariance analysis and effect size calculation will be done.
Survival analysis of time to discontinuation due to treatment-
related side effects will also be done. Subgroup comparisons
will be made to analyze patients who will stop treatment due
to (a) EPS and (b) onset of metabolic syndrome. The
proportion of patients whose metabolic proﬁle worsens
during follow-up will be taken into account.
Mean waist-to-hip ratios in each treatment arm will be
compared, covariance analysis and effect size calculation will
be done. Mean LUNSERS scores in each treatment arm will be
compared, covariance analysis and effect size calculation will
be done. The proportion of patients developing electrocar-
diographic abnormalities in each treatment arm will be
compared. The proportion of patients in each treatment arm
who take antiparkinson drugs or extra psychotropic medica-tion will be used to pragmatically evaluate the onset of EPS or
further psychiatric symptoms.
2.12. Statistical considerations
The main goal of the trial is to test the null hypothesis that
the proportion of cases developing metabolic syndrome is
similar for all three drugs. The criterion for signiﬁcance
(alpha) has been set at 0.05 (2-tailed). Treatments will be
compared using a logistic regression model taking account of
the stratiﬁcation criterion used (trial site).
For all statistical analyses, sites with a small number of
randomized patients will be pooled. The analyses will be
conducted on the ITT population: all those who take at least
one dose of study medication will be included.
If the null hypothesis of the three treatments being equal
is rejected, subsequent analyses will consider each pair of
drugs. Pairwise comparisons between the three treatments
will ensure that the overall Type I error rate is maintained at
0.05 using a Hochberg adjustment for multiple comparisons.
All three comparisons will be signiﬁcant if the largest p-value
is ≤0.05, the two strongest comparisons will be signiﬁcant if
the second-smallest p-value is≤0.025, and only the strongest
comparison will be signiﬁcant if the smallest p-value is
≤0.0167.
As secondary steps, survival analyses using Cox propor-
tional hazards regression models and logistic regressions/
analyses of covariancewill be done on the secondary outcome
measures. In survival analyses, subjects still on treatment one
year after randomization will be censored.
2.12.1. Power calculation
The criteria for signiﬁcance have been set at 0.05 (two-
tailed), corrected for multiple testing, wherever necessary.
On the basis of data extrapolated from recent studies [17,49–
52], it is hypothesized that the percentages of patients who
will develop metabolic syndrome within 12 months will be
25% in the group treated with olanzapine, 15% in the
haloperidol group and 5% in the aripiprazole group.
The ﬁrst step of the primary analysis is an overall 2
degrees of freedom test (using a 2 df Chi square as an
approximation for the logistic regression). The proposed total
sample size of 750 subjects (see below for discussion of the
number) will have a power exceeding 99% to yield a
statistically signiﬁcant result. If a signiﬁcant difference is
found, pairwise comparisons between the study drugs will be
done.
Assuming that (a) the smallest detectable difference is
found in the olanzapine vs. haloperidol comparison (at
p=0.05), (b) the second-smallest difference is found in the
haloperidol vs. aripiprazole (p=0.025), and (c) the largest
difference is between aripiprazole and olanzapine compari-
son (p=0.016), 250 subjects per group will correspond to a
power of, respectively, 80%, 93% and more than 99%. If 7% of
patients on aripiprazole develop metabolic syndrome, the
power to detect a difference against 15% on haloperidol will
be 73%.
To protect against a possible drop-out rate of 5–10%, about
800 patients are required for the study.
On the basis of data extrapolated from the most recent
comparable study [16], it is hypothesized that retention at
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and 30% in the haloperidol group. We assume a retention rate
of 60% in the group treated with aripiprazole. Using the
sample size calculated above (n=800), the measure of
effectiveness adopted as secondary outcome (retention rate
at one year) has a power of N85% to detect signiﬁcant
differences (alpha=0.05/0.025/0.016, two-tailed) between
the three pairwise comparisons, using a logistic regression.
As is common in trials, inclusion of enough patients has
been a problem. Thus, having realized that the original
sample size could not be achieved we had to reduce the
sample to about one third of the original size. Adjustment for
multiple comparisons lowers statistical power. Therefore, to
preserve the study power we cut one of the planned
comparisons and focused on aripiprazole vs. olanzapine,
and vs. haloperidol. The less original comparison between
olanzapine and haloperidol was moved to the secondary
analyses.
We expected to recruit about 260 patients. Assuming that
drop-out rate will be marginal (less than 10%) data from 240
subjects should be available for analyses.
The ﬁrst step of the primary analysis is still an overall 2
degrees of freedom test. The proposed sample of 240 subjects
will have a power of 89% to yield a statistically signiﬁcant
result. If a signiﬁcant difference is found, pairwise compar-
isons between the aripiprazole and the two other compounds
will be done. Assuming that (a) the smallest detectable
difference is found in the aripiprazole (5%) vs. haloperidol
(20%) comparison (at p=0.05), and (b) the largest difference
between aripiprazole (5%) and olanzapine (25%) (at
p=0.025), 80 subjects per group will correspond to a
power of, respectively, 77% and 87%.
3. Results
3.1. Trial registration and conduct
The study protocol, the study manual, the information
brochure and the informed consent form have been approved
by the ethics research review board of the clinical coordinat-
ing center, the Local Health Agency of Genoa (n° 49549,
March 2007). The trial has been approved as an independent
study aimed at improving clinical practice in health care,
according to the deﬁnition of the Italian Ministerial Act 17
December 2004, and has been registered in the National
Monitoring Centre for Clinical Trials and the European Clinical
Trial Database (EudraCT number 2007-000278-22). Local
research ethics review board approval has been obtained for
each participating center.
The study is coordinated by the Epidemiology and Social
Psychiatry Unit of the Mario Negri Institute for Pharmacolog-
ical Research in collaboration with the Department of Mental
Health of the Local Health Agency of Genoa and the
Department of Psychiatry of the University of L'Aquila.
All study sites are monitored on a regular basis, case
record forms are checked and data entered in the central
database. According to Good Clinical Practice, all necessary
procedures to ensure the quality of every aspect of the trial
are complied with. Patient information is only accessible to
the research team and no identifying information is kept with
raw data. Each study investigator keeps records of laboratorytests and ECG diagrams in the patient's ﬁle as original source
documents for the study.
All phases of the GiSAS trial will be recorded following the
CONSORT statement [53].3.2. Study funding and data ownership
The Italian Group for the Study of Second-generation
Antipsychotics (GiSAS) was formed as a loose association in
2006 under the aegis of the Mario Negri Institute for
Pharmacological Research, a non-proﬁt research institute
dedicated to health sciences research. The group currently
comprises 21 members all of whom are part of the GiSAS trial
steering board.
The GiSAS group started working on the protocol and the
Mario Negri Institute accepted to act as sponsor for the study.
As it was not possible obtaining economical support from
national public agencies, funding was ensured through an
unrestricted grant from the drug company Bristol-Myers
Squibb. The grant was accepted by the Mario Negri Institute
on the basis of a contract that guarantees full independence
and data property. Bristol-Myers Squibb had no direct
involvement in the study design, in the data collection,
analysis and interpretation, in writing the present report or in
the decision to submit it for publication. The GiSAS trial was
acknowledged by all the ethics committees involved as an
independent study aimed at improving clinical practice in
health care, according to the deﬁnition of the Italian
Ministerial Act 17 December 2004. This national law
recognizes the public health value of not-for-proﬁt studies
on clinically relevant topics. If certain speciﬁc and account-
able criteria of independence are met, the National Health
Service supports the study conduct, covering part of the
expenses, like the costs of study drugs and insurance. This
permits a large multicenter trial on a relatively low budget,
with no need to rely only on industry funding.
An independent review board has been set up to examine
ethical issues related to the trial. All study data belong to the
GiSAS trial investigators' group who undertake to publish
them as soon as possible. Data will be analyzed and ﬁled by
the Epidemiology and Social Psychiatry Unit of Mario Negri
Institute. Following publication of study results, full data will
be made entirely available to the scientiﬁc community
through unrestricted access to the trial database [54].3.3. Study progress
At the date of revision of this manuscript 43 Italian centers
were active in the study and 54 study investigators had
included at least one patient. At the end of February 2011, the
260th patient was randomized. In total, 170 patients (65%)
had completed the one year follow-up, 10 (4%) had dropped
out and 80 (31%) were still in active follow-up. All available
baseline and follow-up data of the ﬁrst 120 included patients
had already been checked for accuracy and entered in the
study database. The last subject should be included on March
2011 and the trial will be ﬁnished by mid-2012. Study data
are entered as soon as they are collected, so the ﬁrst results
will be available by the end of 2012.
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The purpose of the study was to compare FGAs and SGAs in
termsof tolerability and effectivenesswith the goal of detecting
clinically meaningful differences. Thus, the choice of study
drugs fell on three antipsychotics with different backgrounds
and completely different tolerability proﬁles, primarily aiming
at identifying clinically meaningful differences.
Two recent Cochrane reviews on antipsychotic treatment
for schizophrenia compared the effect of aripiprazole with
SGAs or FGAs [55,56]. Aripiprazole was less effective than
olanzapine, though only in terms of general mental state and
only in the short term [55]. It also caused fewer side-effects
like cholesterol increase, weight gain, sedation and prolactin-
related problems [55]. These ﬁndings are consistent with the
meta-analysis already mentioned onmetabolic side-effects of
SGAs [13]. That review, in fact, found that aripiprazole was
tolerated better than olanzapine in terms of weight gain and
glucose and cholesterol elevation. Both analyses, however,
were based on only two industry-sponsored RCTs and were
biased by selective reporting [49,57]. Compared with FGAs,
aripiprazole differed little in terms of efﬁcacy but presented
advantages in tolerability. It gave fewer EPS and less
hyperprolactinemia and had an advantage in terms of
attrition rates. Compared with haloperidol, however, it did
not show any real advantage in terms of weight gain [56].
Even in the light of newevidencewe can therefore conclude
that the planned comparisons are well-balanced and should
produce innovative and clinically meaningful results.
Adverse reactions like metabolic disturbances or EPS are
extremely common with antipsychotic treatment. Given that
three landmark studies – CATIE, CUtLASS and EUFEST – found
no substantial differences in effectiveness, we planned the
present trial to ﬁnd out whether any one of the selected
antipsychotics would be followed best and would cause less
harm.
Since metabolic side-effects of SGAs (i.e. weight gain,
dyslipidemia and impaired fasting glucose) were emerging
issues and since aripiprazole showed an at least promising
metabolic proﬁle we opted for the choice of metabolic
syndrome as primary endpoint for tolerability. Endpoints
selected for clinical trials must strike a balance between their
scientiﬁc validity and their practical and clinical importance.
The ICH E9 guideline on biostatistics in clinical trials states that
safety/tolerability may sometimes be the primary variable, and
will always be an important consideration [58]. Recently Tyrer
and Kendall (2008) wrote that serious adverse effects of
antipsychotics should be adopted as important outcome
measures [45]. The decision to focus on tolerability and to
adopt a harmful effect as primary negative outcome, although
uncommon, could therefore be valuable for improving the
pharmacological treatment of schizophrenia.
According to the ICH E9 guideline, we indicated one
primary variable – metabolic syndrome – as primary
endpoint [58]. However, as the study design and conduction
focus on drug retention, the GiSAS trial takes account of two
primary endpoints: one for tolerability and one for effective-
ness. Both were used to estimate the sample size because
together they should provide the most clinically important
and convincing evidence directly related to the primary
objective of the trial [46].A trial recruiting subjects with severe, long-lasting
disorders has to deal with previous and current pharmaco-
logical treatments. Patients entering the GiSAS trial should
have a condition appropriate for changing their antipsychotic
treatment. This inclusion criterion is the vital starting point of
the trial: patients should be included in the study only if the
current medication is somehow unsatisfactory. As in CATIE
we decided to allow random assignment to the medication
taken prior to study entry. Given the possibility of not
changing medication, staying on the same antipsychotic had
to be a viable clinical option. On the other hand, those who
were completely satisﬁed with their medication would not
have entered the study. GiSAS participants who were already
taking olanzapine, haloperidol or aripiprazole at baseline
should therefore be not completely satisﬁed with their
medication but did not need absolutely to change it. The
use of the ITT principle allows to preserve randomization
from any subsequent change of the allocated drug. Thus, if
continuing previous medication will turn out to be the wrong
choice clinicians will easily intervene without affecting trial
participation.
The most important principle underlying RCTs is the
concept of clinical equipoise which holds that randomization
is appropriate when the clinician has substantial uncertainty
as to which treatment is likely to provide greatest clinical
beneﬁt. We adopted this principle, which is the cornerstone
of the credibility of all clinical trials, as the leading criterion
for GiSAS recruitment. Thus, a patient was excluded if one of
the study drugs had already proven ineffective or intolerable
or if the treating clinician had any deﬁnite idea of which
antipsychotic would be best.
Some characteristics of the study design might be sources
of bias. Patients and their treating psychiatrists were
unmasked for the assigned treatment, since this better
reﬂects routine clinical practice increasing the trial's external
validity. Knowledge of the treatment allocation and drug
prescribed, however, can inﬂuence the referring clinician's
and participant's assessment and interpretation of effective-
ness and side-effects, and this might in turn inﬂuence
treatment decisions and patients' subsequent use of the
service and outcomes. The only strategy we could adopt to
compensate this bias was to survey clinicians' attitudes
towards antipsychotics with the aim of using these data to
control for possible confounders. A secondary statistical
analysis of the primary outcomes will adjust for clinicians'
expectations of the effectiveness and tolerability of the
various antipsychotic classes.
Post-randomization exclusion is another problematic
issue related to the open nature of the trial. We decided to
include in the ITT analysis only patients who had taken at
least one dose of study medication. Thus, since patients and
their psychiatrists were unblinded, they could choose to opt
out of the trial if their treatment did not turn out to be the one
they wanted. To deal with this, investigators were always
prompted to adhere to the best possible standards of trial
execution. All records on the randomization database (e.g.
failed calls, unregistered and registered randomizations) are
monitored by the study team on a weekly basis in order to
detect any attempts to decipher allocation and to actively
prompt clinicians to prescribe the allocated drug. At this
stage, dropping out of the trial is not an easy option for the
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withdraw informed consent. Moreover, patients for whom
the allocated treatment turns out to be the same cannot be
excluded from the ITT analysis since, by deﬁnition, they have
already taken at least one dose of the investigational drug.
In CATIE phase I, 23% of subjects randomly assigned to
olanzapine and 18% of subjects randomly assigned to
risperidone did not change medication because they already
were on those drugs at study entry. In a post-hoc study,
Essock and colleagues (2006) found that those “stayers” had
signiﬁcantly longer times until discontinuation than those
assigned to switch, and that, when these “stayers” were
removed, differences seen in the original CATIE results were
attenuated [59]. The authors concluded that future random-
ized comparisons should take into account whether medica-
tions being compared were newly initiated or not. Exposure
to treatment prior to the trial seemed, in fact, to advantage
“stayers”, and this could represent another important source
of bias which we will take into consideration.
5. Conclusion
For the last four years, the GiSAS study group has been
committed to the implementation of this multicenter,
pragmatic RCT on aripiprazole, olanzapine and haloperidol
in the long-term treatment of schizophrenia. The trial
mechanism is now fully functional and working, and the
new recruitment target has been reached. Thus, we believe
that trial will add useful knowledge on antipsychotic
treatment for schizophrenic disorders.
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